Antibiotic Therapy for Neonatal Sepsis

Introduction to Antibiotic Recommendations

• The World Health Organization (WHO) recommends ampicillin plus gentamicin as first-line empiric therapy for neonatal sepsis 1, 2
• For hospital-acquired infections, amikacin plus cloxacillin is recommended as an alternative when there is concern for resistant staphylococcal infection 1, 2
• Cefotaxime is recommended as an alternative to gentamicin when there is evidence of gram-negative sepsis 1, 2

Considerations for Linezolid and Tigecycline

• Linezolid should be considered when there is suspected or proven methicillin-resistant Staphylococcus aureus (MRSA) infection resistant to clindamycin 3
• Tigecycline is not recommended in neonates and infants under 8 years due to limited safety and efficacy data in this age group, and risk of permanent tooth discoloration 3
• Tigecycline is not included in pediatric guidelines for neonatal sepsis 1, 2

Clinical Decision-Making

• For a hospitalized 1-month-old with TGA awaiting surgery, hospital-acquired pathogens such as coagulase-negative staphylococci and gram-negative bacteria are most likely 4, 6
• The presence of ascites suggests possible peritoneal involvement, and TGA indicates cardiac involvement requiring careful antibiotic selection 2

Adverse Effects and Monitoring

• Tigecycline can cause permanent tooth discoloration in developing teeth 3
• Linezolid requires monitoring of complete blood count with platelet monitoring during therapy 2
• Blood cultures should be taken before and during treatment to confirm pathogen eradication 2

Key Recommendations

• Delaying antibiotic initiation while awaiting culture results can increase mortality 2
• Using broad-spectrum antibiotics without appropriate indications can lead to resistance 4, 6
• Failing to adjust therapy based on culture results and clinical response can lead to treatment failure 2